Client news

A&O Shearman advises Shionogi on its equity investment into, and hearing function collaboration with, Salubritas

A&O Shearman advises Shionogi on its equity investment into, and hearing function collaboration with, Salubritas
Published Date
Jan 20 2026
Related people
Image of Tokutaka Ito
Tokutaka ItoPartner, Tokyo
Image of Nicole Daley
Nicole DaleyPartner, Boston
Image of Jim Ford
Jim FordPartner, London
Image of Megan McMellon
Megan McMellonSenior Associate, London
Image of Kotaro Tsukui
Kotaro TsukuiSenior Associate, Tokyo
Image of Mara Goodman
Mara GoodmanAssociate, New York
Image of James Heaney
James HeaneyAssociate, Boston
Image of Millie Fantham
Millie FanthamAssociate, London
A&O Shearman has advised Shionogi & Co., Ltd. (Shionogi) on its equity investment into, and joint research and development agreement with, Salubritas Therapeutics Inc. (Salubritas).

Under the joint research and development agreement, Salubritas and Shionogi will collaborate to develop a therapeutic drug that regenerates hair cells and improves hearing function.

Tokutaka Ito (partner, Tokyo) and Nicole Daley (partner, Boston) led the team advising Shionogi on the equity investment into Salubritas, supported by Kotaro Tsukui (senior associate, Tokyo), Mara Goodman (associate, New York) and James Heaney (associate, Boston).

Jim Ford (partner, London) and Megan McMellon (senior associate, London) led the team advising Shionogi on the joint research and development agreement, supported by Millie Fantham (associate, London) and Bella Gropper (associate, London).

"We’re thrilled to support Shionogi on its investment and R&D collaboration with Salubritas. By aligning incentives and reinforcing the IP foundations, this partnership is set to accelerate novel therapies for hearing loss from discovery to patients."

Related capabilities